ATOSSA THERAPEUTICS, INC.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 1448 NW MARKET STREET, SEATTLE, WA, 98107
Mailing Address 1448 NW MARKET STREET, SEATTLE, WA, 98107
Phone 206.588.0256
Fiscal Year End 1231
EIN 264753208
Financial Overview
FY2024
$76.44M
Total Assets
$117.96M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | February 11, 2026 | View on SEC |
| 4/A Insider transaction amendment | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 26, 2026 | View on SEC |
| 4 Insider stock transaction report | January 22, 2026 | View on SEC |
| 8-K Current report of material events | January 9, 2026 | View on SEC |
| 8-K Current report of material events | January 6, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | December 22, 2025 | View on SEC |
| 8-K Current report of material events | December 4, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| 8-K Current report of material events | November 12, 2025 | View on SEC |
Material Events
8-K Strategy Change February 11, 2026
High Impact
- Strategic pivot to high-value rare diseases (DMD, MAS) with (Z)-endoxifen, optimizing resource allocation.
- FDA Rare Pediatric Disease and Orphan Drug Designations for DMD, offering potential for a highly valuable Priority Review Voucher (PRV).
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.